A single intranasal inoculation with a paramyxoviras-vectored vaccine protects guinea pigs against a lethal-dose ebola virus challenge

Alexander Bukreyev, Lijuan Yang, Sherif R. Zaki, Wun Ju Shieh, Pierre E. Rollin, Brian R. Murphy, Peter L. Collins, Anthony Sanchez

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

To determine whether intranasal inoculation with a paramyxovirus-vectored vaccine can induce protective immunity against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to express either the EV structural glycoprotein (GP) by itself (HPIV3/EboGP) or together with the EV nucleoprotein (NP) (HPIV3/EboGP-NP). Expression of EV GP by these recombinant viruses resulted in its efficient incorporation into virus particles and increased cytopathic effect in Vero cells. HPIV3/EboGP was 100-fold more efficiently neutralized by antibodies to EV than by antibodies to HPIV3. Guinea pigs infected with a single intranasal inoculation of 105.3 PFU of HPIV3/EboGP or HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 103 PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge. The highly effective immunity achieved with a single vaccine dose suggests that intranasal immunization with live vectored vaccines based on recombinant respiratory viruses may be an advantageous approach to inducing protective responses against severe systemic infections, such as those caused by hemorrhagic fever agents.

Original languageEnglish (US)
Pages (from-to)2267-2279
Number of pages13
JournalJournal of Virology
Volume80
Issue number5
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Ebolavirus
Human parainfluenza virus 3
lethal dose
guinea pigs
Guinea Pigs
Vaccines
vaccination
vaccines
viruses
nucleoproteins
Nucleoproteins
glycoproteins
immunity
Respirovirus
Immunity
Ebola Hemorrhagic Fever
antibodies
cytopathogenicity
viremia
live vaccines

ASJC Scopus subject areas

  • Immunology

Cite this

A single intranasal inoculation with a paramyxoviras-vectored vaccine protects guinea pigs against a lethal-dose ebola virus challenge. / Bukreyev, Alexander; Yang, Lijuan; Zaki, Sherif R.; Shieh, Wun Ju; Rollin, Pierre E.; Murphy, Brian R.; Collins, Peter L.; Sanchez, Anthony.

In: Journal of Virology, Vol. 80, No. 5, 03.2006, p. 2267-2279.

Research output: Contribution to journalArticle

Bukreyev, Alexander ; Yang, Lijuan ; Zaki, Sherif R. ; Shieh, Wun Ju ; Rollin, Pierre E. ; Murphy, Brian R. ; Collins, Peter L. ; Sanchez, Anthony. / A single intranasal inoculation with a paramyxoviras-vectored vaccine protects guinea pigs against a lethal-dose ebola virus challenge. In: Journal of Virology. 2006 ; Vol. 80, No. 5. pp. 2267-2279.
@article{92830c07dcfa4678b32da76684020bbd,
title = "A single intranasal inoculation with a paramyxoviras-vectored vaccine protects guinea pigs against a lethal-dose ebola virus challenge",
abstract = "To determine whether intranasal inoculation with a paramyxovirus-vectored vaccine can induce protective immunity against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to express either the EV structural glycoprotein (GP) by itself (HPIV3/EboGP) or together with the EV nucleoprotein (NP) (HPIV3/EboGP-NP). Expression of EV GP by these recombinant viruses resulted in its efficient incorporation into virus particles and increased cytopathic effect in Vero cells. HPIV3/EboGP was 100-fold more efficiently neutralized by antibodies to EV than by antibodies to HPIV3. Guinea pigs infected with a single intranasal inoculation of 105.3 PFU of HPIV3/EboGP or HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 103 PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge. The highly effective immunity achieved with a single vaccine dose suggests that intranasal immunization with live vectored vaccines based on recombinant respiratory viruses may be an advantageous approach to inducing protective responses against severe systemic infections, such as those caused by hemorrhagic fever agents.",
author = "Alexander Bukreyev and Lijuan Yang and Zaki, {Sherif R.} and Shieh, {Wun Ju} and Rollin, {Pierre E.} and Murphy, {Brian R.} and Collins, {Peter L.} and Anthony Sanchez",
year = "2006",
month = "3",
doi = "10.1128/JVI.80.5.2267-2279.2006",
language = "English (US)",
volume = "80",
pages = "2267--2279",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - A single intranasal inoculation with a paramyxoviras-vectored vaccine protects guinea pigs against a lethal-dose ebola virus challenge

AU - Bukreyev, Alexander

AU - Yang, Lijuan

AU - Zaki, Sherif R.

AU - Shieh, Wun Ju

AU - Rollin, Pierre E.

AU - Murphy, Brian R.

AU - Collins, Peter L.

AU - Sanchez, Anthony

PY - 2006/3

Y1 - 2006/3

N2 - To determine whether intranasal inoculation with a paramyxovirus-vectored vaccine can induce protective immunity against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to express either the EV structural glycoprotein (GP) by itself (HPIV3/EboGP) or together with the EV nucleoprotein (NP) (HPIV3/EboGP-NP). Expression of EV GP by these recombinant viruses resulted in its efficient incorporation into virus particles and increased cytopathic effect in Vero cells. HPIV3/EboGP was 100-fold more efficiently neutralized by antibodies to EV than by antibodies to HPIV3. Guinea pigs infected with a single intranasal inoculation of 105.3 PFU of HPIV3/EboGP or HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 103 PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge. The highly effective immunity achieved with a single vaccine dose suggests that intranasal immunization with live vectored vaccines based on recombinant respiratory viruses may be an advantageous approach to inducing protective responses against severe systemic infections, such as those caused by hemorrhagic fever agents.

AB - To determine whether intranasal inoculation with a paramyxovirus-vectored vaccine can induce protective immunity against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to express either the EV structural glycoprotein (GP) by itself (HPIV3/EboGP) or together with the EV nucleoprotein (NP) (HPIV3/EboGP-NP). Expression of EV GP by these recombinant viruses resulted in its efficient incorporation into virus particles and increased cytopathic effect in Vero cells. HPIV3/EboGP was 100-fold more efficiently neutralized by antibodies to EV than by antibodies to HPIV3. Guinea pigs infected with a single intranasal inoculation of 105.3 PFU of HPIV3/EboGP or HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 103 PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge. The highly effective immunity achieved with a single vaccine dose suggests that intranasal immunization with live vectored vaccines based on recombinant respiratory viruses may be an advantageous approach to inducing protective responses against severe systemic infections, such as those caused by hemorrhagic fever agents.

UR - http://www.scopus.com/inward/record.url?scp=33144465928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144465928&partnerID=8YFLogxK

U2 - 10.1128/JVI.80.5.2267-2279.2006

DO - 10.1128/JVI.80.5.2267-2279.2006

M3 - Article

VL - 80

SP - 2267

EP - 2279

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 5

ER -